Exosomes Market Size Report 2021-2028 | Share, Growth Factors, Trends, Restraining Factors, Competitive Landscape, Revenue, Forecast Analysis
18 oct. 2021 06h05 HE
|
Fortune Business Insights
Pune, India, Oct. 18, 2021 (GLOBE NEWSWIRE) -- The global exosomes market size is expected to gain momentum owing to the rising prevalence of cancer during the forecast period. This information is...
Global Exosome Pipeline Report 2021: Insights on 50+ Companies and 50+ Pipeline Drugs | DelveInsight
25 janv. 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Global Exosome Pipeline Report 2021: Insights on 50+ Companies and 50+ Pipeline Drugs | DelveInsight Exosomes Pipeline is robust and possesses...
Forecast Report [2019-2026] Exosomes Market Size, Share, Growth, Trends, Competitive Analysis, Revenue by Fortune Business Insights™
13 oct. 2020 06h48 HE
|
Fortune Business Insights
Pune, Oct. 13, 2020 (GLOBE NEWSWIRE) -- The global exosomes market is projected to witness rapid growth in the coming years driven by the massive investments in product R&D. The increasing...
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
19 déc. 2019 13h14 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics...
Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market
17 déc. 2019 13h52 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics...
Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7
01 nov. 2019 09h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor Therapeutics to Present at Upcoming Conferences
06 sept. 2019 07h30 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy
15 juil. 2019 06h00 HE
|
Capricor Therapeutics, Inc.
--Interim Analysis Showed Statistically Significant Improvements in the Performance of the Upper Limb, Grip Strength and Inspiratory Flow Reserve in the Randomized Double-Blind Placebo Controlled...
Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
13 mai 2019 16h00 HE
|
Capricor Therapeutics, Inc.
On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 13, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
06 mai 2019 16h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...